Get started
Author

Karen Afenjar

Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2–Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC—A Randomized Phase III Trial
2015 · J. Randolph Hecht, Yung-Jue Bang, et al. · Journal of Clinical Oncology · 642
Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial
2017 · Sara A Hurvitz, Miguel Martin, et al. · The Lancet Oncology · 560
PDF
Ribociclib plus Endocrine Therapy in Early Breast Cancer
2024 · Dennis Slamon, Oleg Lipatov, et al. · New England Journal of Medicine · 476
Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study
2019 · Sara A. Hurvitz, Miguel Martin, et al. · Journal of Clinical Oncology · 262
PDF
Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) in HER2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma (AC): The TRIO-013/LOGiC Trial.
2013 · J. Randolph Hecht, Yung-Jue Bang, et al. · Journal of Clinical Oncology · 126
Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2− early breast cancer
2023 · Dennis J. Slamon, Peter A. Fasching, et al. · Therapeutic Advances in Medical Oncology · 118
PDF
Association of Proton Pump Inhibitors and Capecitabine Efficacy in Advanced Gastroesophageal Cancer: Secondary Analysis of the TRIO-013/LOGiC Randomized Clinical Trial
2016 · Michael P. Chu, J. Randolph Hecht, et al. · JAMA Oncology · 109
PDF
Pathologic complete response (pCR) rates after neoadjuvant trastuzumab emtansine (T-DM1 [K]) + pertuzumab (P) vs docetaxel + carboplatin + trastuzumab + P (TCHP) treatment in patients with HER2-positive (HER2+) early breast cancer (EBC) (KRISTINE).
2016 · Sara A. Hurvitz, Miguel Martin, et al. · Journal of Clinical Oncology · 49
HER2 Status in Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma for Entry to the TRIO-013/LOGiC Trial of Lapatinib
2016 · Michael F. Press, Catherine E. Ellis, et al. · Molecular Cancer Therapeutics · 43
PDF
Health-Related Quality of Life in Patients with HR+/HER2− Early Breast Cancer Treated with Ribociclib Plus a Nonsteroidal Aromatase Inhibitor: Results from the NATALEE Trial
2025 · Peter A. Fasching, Dennis Slamon, et al. · Clinical Cancer Research · 16
VP3-2023: Health-related quality of life (HRQoL) in the phase III NATALEE study of adjuvant ribociclib (RIB) plus a nonsteroidal aromatase inhibitor (NSAI) vs NSAI alone in patients (pts) with HR+/HER2- early breast cancer (EBC)
2023 · P.A. Fasching, D. Slamon, et al. · Annals of Oncology · 7
PDF
Results of a phase I / II and pharmacokinetic study of vinflunine (VFL) in combination with cisplatin (CDDP) for primary treatment of advanced non-small cell lung cancer (NSCLC)
2004 · R. Ramlau, P.-J. Souquet, et al. · Journal of Clinical Oncology · 7
113MO NATALEE update: Safety and treatment (tx) duration of ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2− early breast cancer (EBC)
2024 · C.H. Barrios, N. Harbeck, et al. · ESMO Open · 6
PDF
Neoadjuvant trastuzumab (H), pertuzumab (P), and chemotherapy versus trastuzumab emtansine (T-DM1) and P in human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC): Final outcome results from the phase III KRISTINE study.
2019 · Sara A. Hurvitz, Miguel Martin, et al. · Journal of Clinical Oncology · 6
Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) in HER2 positive advanced or metastatic gastric (A/MGC), esophageal (EAC), or gastroesophageal (GEJ) adenocarcinoma: The LOGiC trial.
2013 · J. Randolph Hecht, Yung-Jue Bang, et al. · Journal of Clinical Oncology · 6
6584 A phase III study of CapeOx +/− lapatinib in HER2 positive locally-advanced/metastatic upper gastrointestinal adenocarcinoma: interim safety results
2009 · J. Hecht, Y. Bang, et al. · European Journal of Cancer Supplements · 6
242P Clinical outcomes in patients (pts) with HR+/HER2− early breast cancer (EBC) by prior systemic treatment (tx): A subgroup analysis of the NATALEE trial
2024 · N.P. McAndrew, S. Chia, et al. · Annals of Oncology · 2
PDF
Proton Pump Inhibitor (Ppis) Therapy May Impair Capecitabine (Cape) Efficacy in Metastatic Gastroesophageal Cancer (Gec), Results from the Trio-013/Logic Trial
2014 · M.P. Chu, J.R. Hecht, et al. · Annals of Oncology · 2
PDF
Safety and treatment duration of ribociclib + nonsteroidal aromatase inhibitor in HR+/HER2− early breast cancer: a phase 3 randomized controlled trial (NATALEE)
2026 · H. S. Rugo, N. Harbeck, et al. · Breast Cancer Research · 1
Abstract PD12-06: Treatment-related amenorrhea with T-DM1 plus pertuzumab (KP) is lower than with docetaxel/carboplatin/trastuzumab/pertuzumab (TCHP) in the phase III neoadjuvant KRISTINE trial
2021 · Sara A Hurvitz, Rodrigo Fresco, et al. · Cancer Research · 1
Post-hoc analyses of overall survival (OS) and progression-free survival (PFS) in the TRIO-013/LOGiC trial of lapatinib (L) in combination with capecitabine plus oxaliplatin (CapeOx).
2015 · Yung-Jue Bang, Shukui Qin, et al. · Journal of Clinical Oncology · 1
P-566 Vinflunine (VFL) in combination with carboplatin (CBDCA) for treatment of advanced non-small cell lung cancer (NSCLC) in chemonaive patients (pts): Phase I and pharmacokinetic study
2005 · G. Robinet, K. Afenjar, et al. · Lung Cancer · 1
Supplementary Data 1 from Health-Related Quality of Life in Patients with HR+/HER2− Early Breast Cancer Treated with Ribociclib Plus a Nonsteroidal Aromatase Inhibitor: Results from the NATALEE Trial
2025 · Peter A. Fasching, Dennis Slamon, et al.
Data from Health-Related Quality of Life in Patients with HR+/HER2− Early Breast Cancer Treated with Ribociclib Plus a Nonsteroidal Aromatase Inhibitor: Results from the NATALEE Trial
2025 · Peter A. Fasching, Dennis Slamon, et al.
Supplementary Data. from HER2 Status in Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma for Entry to the TRIO-013/LOGiC Trial of Lapatinib
2023 · Michael F. Press, Catherine E. Ellis, et al.
Works count: 27
Citation count: 2,447
H-index: 10
I10-index: 10
Year
Topic
Type